Retatrutide (LY3437943) is a potential triple agonist peptide, an investigational drug of Eli Lilly that activates three receptors simultaneously, namely, GLP-1, GIP, and glucagon. This multi-receptor strategy, with an aim of attaining higher weight loss compared to the existing dual or single agonists, combines appetite suppression, enhanced insulin sensitivity, and augmented energy expenditure.
By April 2026, research grade Retatrutide has already achieved some of the major Phase 3 trials in the TRIUMPH program. Experts have characterized the results as some of the most impressive weight-loss data ever reported in an anti-obesity drug.
Note: Retatrutide is not FDA-approved for any indication and is still in the investigational stage. Any data below is informed by publicly available clinical trial data and topline results.
Table of Contents
Phase 3 Outcomes: Excellent Weight Loss Statistics.
Retatrutide (12 mg/week) was tested in a landmark study, TRIUMPH-1 (72 weeks, obese or overweight with comorbidities), where the highest dose (12 mg/week) yielded an average weight loss of about 24 percent compared to baseline. A large percentage of participants had achieved clinically significant results:
- Over 60% lost ≥20% of body weight
- Around 35–40% lost ≥25% of body weight
The lower dosages (4 mg and 8 mg) also produced meaningful results with average weight losses of 17-21 percent.
The other cardiometabolic advantages were:
- Up to 2.0% changes in HbA1c of type 2 diabetes patients.
- Notable decreases in liver fat content (measured by MRI)
- Decreases in triglycerides, blood pressure, and waist circumference (average 18-22 cm)
These results may indicate that Retatrutide could be one of the most potent weight-loss agents that have been investigated to date, but all Phase 3 data are yet to be published in a full peer-reviewed journal.
How Retatrutide Works
Retatrutide’s triple agonist mechanism is its main differentiator:
- GLP-1 receptor: Decreases appetite and delays gastric emptying.
- stimulation of GIP receptors: stimulates insulin release and promotes lipid metabolism.
- Stimulation of glucagon receptors: Energizes and accelerates the breakdown of fat (lipolysis).
It is thought that the glucagon component is responsible for the extra weight loss observed with dual GLP-1/GIP agonists by increasing calorie burning but maintaining hunger.
Research-Based Benefits of Retatrutide
In addition to weight loss, Phase 3 and previous trials have indicated improvements in various fields:
1. Improved Glycemic Control
The HbA1c improved significantly (up to 2.0) in individuals with type 2 diabetes, and many individuals achieved better glycemic goals.
2. Decrease in Liver Fat.
Initial imaging evidence indicated significant reductions in hepatic fat content, which should be pursued in non-alcoholic fatty liver disease (NAFLD/MASH).
3. Cardiometabolic Risk Factor Improvement
Systolic blood pressure and triglycerides reductions and positive changes in lipid profiles were observed in the studies.
4. May have Better Lean Mass Preservation.
In some sub-studies with resistance training, Retatrutide demonstrated somewhat positive lean mass retention over some other incretin-based treatment.
5. Modulating the Appetite and Reward Pathway.
Imaging studies and patient-reported outcomes indicate that there are strong effects on food cravings and reward signaling.
Note: These advantages are based on clinical trial results. Ongoing studies are assessing long-term real-world outcomes and complete safety profiles.
Safety Profile and Side Effects
Retatrutide has a safety profile that is usually similar to the incretin group of drugs. The gastrointestinal side effects are the most common:
- Nausea, vomiting, diarrhea, and constipation (mostly mild to moderate and lessened with the gradual escalation of the dose).
Gallbladder and pancreatitis risk events do not seem different compared to other GLP-1/GIP agonists. None of the significant new safety signals have been revealed during Phase 3 that are not related to the class. Eli Lilly is also running long-term cardiovascular outcome trials (TRIUMPH-CVOT) to further determine heart safety.
FDA Timeline and Approval Outlook (2026)
Eli Lilly has announced that it expects to file a New Drug Application (NDA) with the FDA in the second half of 2026. With a normal review schedule, a possible decision might be made in late 2027 or early 2028.
Since Retatrutide is a first-in-class triple agonist, the FDA will perform an in-depth examination of the entire safety database. Chronic weight management approval would probably require post-marketing study requirements.
Final Thoughts
Some of the highest percentages of weight-loss have been documented with retatrutide in Phase 3 obesity trials. The triple-agonist effect of it is a promising development towards dealing with the multifaceted biology of obesity and metabolism.
Although recent FDA news about peptide restrictions has generated increased industry debate, Retatrutide itself is undergoing a normal new drug approval process. The next several months will be significant because more Phase 3 data will be disclosed and NDA will be ready.
To stay up-to-date on the official news, refer to the investor communications of Eli Lilly and the FDA news.
The information in this article is all founded on publicly available clinical trial data and news as of April 2026. Retatrutide is still experimental and not validated to be used in any other area other than in clinical trials.
References
1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
https://pubmed.ncbi.nlm.nih.gov/37351564
2. Lilly Press Release. TRIUMPH Phase 3 Program Topline Results (2026).
3. Reuters (March 31, 2026). U.S. FDA is expected to lift restriction on certain peptides.
4. The New York Times (March 31, 2026). FDA Expected to Lift Restrictions on Certain Peptides.
https://www.nytimes.com/2026/03/31/health/fda-peptides-compounding-restrictions.html
5. Additional data from TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 trials (Eli Lilly, 2026).
